Translational Research in Oncology

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Translational Research in Oncology sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

Translational Research in Oncology: 8 sponsored US clinical trials, none currently recruiting.

Translational Research in Oncology sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ovarian Neoplasms, with 1 trials.

Upper-quartile sponsor footprint

Translational Research in Oncology sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

TERMINATED Phase 3

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

NCT04777851
COMPLETED Early Phase 1

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

NCT03004534
TERMINATED Phase 2

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

NCT02900560
TERMINATED Phase 2

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

NCT02115048
COMPLETED Phase 2

Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer

NCT00777049
TERMINATED Phase 2

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

NCT00777335
COMPLETED Phase 2

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

NCT00719212
TERMINATED Phase 2

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

NCT00718523

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6
Phase 3 1

Therapeutic Areas

Ovarian Neoplasms 1
Breast Cancer Female 1

How the Translational Research in Oncology early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 3 completed (38%).

Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Ovarian Neoplasms (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Translational Research in Oncology: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Translational Research in Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Translational Research in OncologyAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Translational Research in Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Translational Research in Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Translational Research in Oncology page

8 registered trials is a research-attention snapshot, not an endorsement of Translational Research in Oncology or any single study.

  • None of Translational Research in Oncology's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Ovarian Neoplasms is the condition Translational Research in Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ovarian Neoplasms trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Translational Research in Oncology pipeline card: 8 registered trials from official public datasets.Report a data error.